The Monba is an ethnic minority with a long history. Their name, 'Monba', pronounced 'Menba' in Chinese, derives from Tibetan and refers to the people living in Menyu in the lower reaches of the Yarlong Tsangpo River. The Monba now occupy ...
Tags: The Monba Nationality, Language, Belief, Clothes, Food, Crafts, Customs
Ranbaxy Pharmaceuticals,a wholly owned subsidiary of Ranbaxy Laboratories(RLL),has launched authorized generic pioglitazone hydrochloride tablets in the US market under an agreement with Takeda Pharmaceuticals US. Pioglitazone ...
Tags: Ranbaxy Pharmaceuticals, Ranbaxy Laboratories, Takeda Pharmaceuticals
UK-based Medicines and Healthcare products Regulatory Agency(MHRA)has granted marketing authorization to pSivida for its Iluvien insert. The marketing authorization follows the recently announced approval in Austria. The approvals were ...
Tags: pSivida Iluvien insert, MHRA, intravitreal insert, Iluvien
Merck has signed a licensing agreement with AiCuris for the worldwide development and commercialisation rights of candidates in AiCuris' Human Cytomegalovirus (HCMV) portfolio. The HCMV portfolio includes letermovir (AIC246), an oral, ...
The Jingpo ethnic minority (population about 132,000 according to the year 2000 census) lives mainly in the Dehong, Dai-Jingpo Autonomous Prefectures with some in the Nujiang Lisu Autonomous Prefecture, as well as in Myanmar. Their native ...
Tags: The Jingpo Nationality, Economy, Religion, Crafts, Clothes, Festivals
KineMed has entered into a multi-year R&D collaboration GlaxoSmithKline (GSK) to develop kinetic biomarkers. The collaboration will apply KineMed's biomarker discovery platform in therapeutic areas of interest to GSK. KineMed president ...
Tags: kinetic biomarkers, GlaxoSmithKline, KineMed's technology
GlaxoSmithKline (GSK) has entered into a drug discovery alliance with Yale to design a potential new class of medicines that degrade disease-causing proteins. Under the collaboration, GSK integrates its expertise in medicinal chemistry ...
Tags: Yale University, Drug Discovery Alliance, protein-degrading drug
Australian Therapeutic Goods Administration (TGA) has cleared Genzyme's once daily oral Aubagio 14mg dose for the treatment of relapsing multiple sclerosis (MS). Aubagio, which has anti-inflammatory properties, is expected to minimize ...
Ten biopharmaceutical companies, Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi have established a non-profit organization ...
Tags: biopharmaceutical companies, non-profit organization, new medicines
The Korea Food and Drug Administration (KFDA) announced a re-categorisation plan for medicines, which allows emergency contraception pills, known as morning-after pills, to be sold OTC, while birth control pills will require a visit to the ...
European Medicines Agency's (EMA) Committee for Orphan Medicinal Products has announced positive opinion for granting orphan disease designation to Aspireo Pharmaceuticals' Somatoprim for the treatment of acromegaly. Somatoprim, the ...
The Scottish Medicines Consortium (SMC) has approved the use of Alcon's Nevanac in patients suffering from diabetes to minimize the possibility of postoperative macular oedema (MO) coupled with cataract surgery. The approval allows the ...
Tags: The Scottish Medicines Consortium, diabetic cataract patients, Medicine
The European Medicines Agency (EMA) has granted orphan drug status to AlphaCore Pharma's ACP-501 (rhLCAT) to treat familial LCAT deficiency (FLD). FLD causes lipid deposition in eyes, red blood cells and kidneys which can lead to corneal ...
Tags: EMA, orphan drug status, AlphaCore FLD
Australian Pesticides and Veterinary Medicines Authority (APVMA) has issued a permit to Cotton Australia for the use of various herbicides for the control of weeds in pigeon pea Bollgard II cotton refuges and trap crops from October 12, ...
Tags: Australian Pesticides, Veterinary Medicines Authority, Cotton Australia
The USFDA has approved Abbott's Humira (adalimumab) for the treatment of adult patients with moderate to severe Ulcerative Colitis (UC) when certain other medicines have not worked well enough. Humira, which works by inhibiting tumour ...
Tags: FDA, Abbott Humira, Ulcerative Colitis